Regenerative Sciences, Inc., commonly referred to as Regenexx, is a pioneering leader in the field of regenerative medicine, headquartered in the United States. Founded in 2005, the company has established itself as a key player in the development of advanced stem cell therapies and regenerative treatments, primarily focusing on orthopaedic and musculoskeletal conditions. With a commitment to innovation, Regenexx offers a range of unique services, including non-surgical stem cell procedures that harness the body’s natural healing capabilities. Their proprietary techniques set them apart in the industry, providing patients with effective alternatives to traditional surgical interventions. Recognised for its significant contributions to regenerative medicine, Regenexx has built a strong market position, serving patients across various operational regions in the US. The company continues to lead the way in research and clinical applications, making strides in improving patient outcomes and advancing the field.
How does Regenerative Sciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Insurance Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Regenerative Sciences, Inc.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Regenerative Sciences, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary, Regenerative Sciences, Inc. may inherit climate commitments and emissions data from its parent organisation; however, no specific details or figures have been provided regarding these cascaded data sources. The lack of emissions reporting and reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy or may rely on broader corporate family commitments for guidance. In the context of the industry, it is essential for organisations like Regenerative Sciences, Inc. to establish clear climate commitments and reduction targets to align with global sustainability goals and enhance their environmental accountability.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Regenerative Sciences, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
